<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712006</url>
  </required_header>
  <id_info>
    <org_study_id>CR108840</org_study_id>
    <secondary_id>64304500CRD1003</secondary_id>
    <nct_id>NCT04712006</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants</brief_title>
  <official_title>Phase 1, Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic following single subcutaneous&#xD;
      administration of Dose 1 or Dose 2 of JNJ-64304500 in healthy Chinese adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor Decision.&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Concentration of JNJ-64304500</measure>
    <time_frame>Up to Day 113</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of JNJ-64304500 using a validated, specific and sensitive immunoassay method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 113</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antibodies to JNJ-64304500</measure>
    <time_frame>Up to Day 113</time_frame>
    <description>Number of participants with antibodies to JNJ-64304500 will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: JNJ-64304500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single subcutaneous (SC) Dose 1 of JNJ-64304500 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: JNJ-64304500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single SC Dose 2 of JNJ-64304500 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64304500</intervention_name>
    <description>Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.</description>
    <arm_group_label>Cohort 1: JNJ-64304500</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-64304500</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female Chinese participants whose parents and maternal and paternal&#xD;
             grandparents are of Chinese ethnicity&#xD;
&#xD;
          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted&#xD;
             reproduction during the study and until Day 113&#xD;
&#xD;
          -  A male participant must agree not to donate sperm for the purpose of reproduction and&#xD;
             must wear a condom when engaging in any activity that allows for passage of ejaculate&#xD;
             to another person during the study and until Day 113&#xD;
&#xD;
          -  A woman must have a negative highly sensitive serum beta-human chorionic gonadotropin&#xD;
             (hCG) at screening and a negative urine pregnancy test on Day -1 and while enrolled in&#xD;
             this study&#xD;
&#xD;
          -  Nonsmoker or agree to smoke no more than 10 cigarettes or equivalent of e-cigarettes,&#xD;
             or 2 cigars, or 2 pipes of tobacco per day throughout the study, if the inpatient unit&#xD;
             allows. However, if smoking is not allowed in the inpatient unit, smokers will not be&#xD;
             allowed to smoke while inpatient and cannot use nicotine replacement products during&#xD;
             the inpatient period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant medical illness or medical disorders the&#xD;
             investigator considers should be exclude the participant, including (but not limited&#xD;
             to) liver or renal insufficiency, significant cardiac, vascular, pulmonary,&#xD;
             gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or&#xD;
             metabolic disturbances&#xD;
&#xD;
          -  Any condition for which, in the opinion of the investigator, participation would not&#xD;
             be in the best interest of the participant (example, compromise the well-being) or&#xD;
             that could prevent, limit, or confound the protocol-specified assessments&#xD;
&#xD;
          -  Had major illness or surgery, (example, requiring general anesthesia) within 12 weeks&#xD;
             before screening, or will not have fully recovered from illness or surgery, or has&#xD;
             surgery planned during the time the participant is expected to participate in the&#xD;
             study or until Day 113&#xD;
&#xD;
          -  Plans to undergo non-major elective surgery within 4 weeks prior to study intervention&#xD;
             administration through the end of the study&#xD;
&#xD;
          -  Known or suspected allergies, hypersensitivity or intolerance to JNJ-64304500 or any&#xD;
             biologic medication, or known allergies or clinically significant reactions to murine,&#xD;
             chimeric, or human proteins, mAbs or antibody fragments, or to any components of the&#xD;
             formulation of JNJ-64304500 and its excipients used in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108840</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

